Divergent asymmetric synthesis of (–)-ganocins A–C and (+)-cochlearol B via a non-biomimetic strategy
Abstract
Natural products are of substantial value in drug discovery screening campaigns. Their three-dimensional structures exhibit high complementarity with target proteins, via a multimodal combination of hydrogen bonds, hydrophobic contacts, electrostatic interactions, and van der Waals interactions. Skeletal diversity directly determines the three-dimensional shape diversity of compound libraries. Therefore, the rapid access to distinct molecular skeletons significantly increases the odds of drug discovery. Ganocins A–C and cochlearol B, Ganoderma meroterpenoids, feature distinct skeletons and diverse bioactivities. Despite tremendous efforts by synthetic chemists, a unified asymmetric synthetic strategy towards all four members has remained elusive. Here, we report the unified, asymmetric total synthesis of (–)-ganocins A–C and (+)-cochlearol B via a non-biomimetic strategy, featuring diastereoselective oxa-Michael addition, acid-controlled divergent cascade aldol/etherification cyclization or aldol/dehydration, and SmI ₂ -mediated 4- exo -trig reductive cross-coupling. This meticulously designed synthetic strategy establishes a general solution to a problem previously deemed intractable by biomimetic approaches.
Related
- Magnetically guided programmable thermomechanical protection enabled by biomimetic asymmetric design
- General Asymmetric Synthesis of Noncanonical Amino Acids
- Dehydration triggers anomalous subdiffusion in biomimetic cell membranes
- Probing and modeling cell–cell communication in 2D biomimetic tissues
- Biomimetic remodelling of lipid membranes using DNA nanostructures
BibTeX
@article{xu2026divergent,
title = {{Divergent asymmetric synthesis of (–)-ganocins A–C and (+)-cochlearol B via a non-biomimetic strategy}},
author = {Hailong Xu and Yu Yang and Jinghua Wu and Huanfeng Jiang and Zhiqiang Ma},
journal = {Nature Communications},
year = {2026},
month = oct,
doi = {10.1038/s41467-026-78287-1},
url = {https://www.nature.com/articles/s41467-026-78287-1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Divergent asymmetric synthesis of (–)-ganocins A–C and (+)-cochlearol B via a non-biomimetic strategy
AU - Hailong Xu
AU - Yu Yang
AU - Jinghua Wu
AU - Huanfeng Jiang
AU - Zhiqiang Ma
PY - 2026
DA - 2026/10/15
JO - Nature Communications
DO - 10.1038/s41467-026-78287-1
UR - https://www.nature.com/articles/s41467-026-78287-1
AB - Natural products are of substantial value in drug discovery screening campaigns. Their three-dimensional structures exhibit high complementarity with target proteins, via a multimodal combination of hydrogen bonds, hydrophobic contacts, electrostatic interactions, and van der Waals interactions. Skeletal diversity directly determines the three-dimensional shape diversity of compound libraries. Therefore, the rapid access to distinct molecular skeletons significantly increases the odds of drug discovery. Ganocins A–C and cochlearol B, Ganoderma meroterpenoids, feature distinct skeletons and diverse bioactivities. Despite tremendous efforts by synthetic chemists, a unified asymmetric synthetic strategy towards all four members has remained elusive. Here, we report the unified, asymmetric total synthesis of (–)-ganocins A–C and (+)-cochlearol B via a non-biomimetic strategy, featuring diastereoselective oxa-Michael addition, acid-controlled divergent cascade aldol/etherification cyclization or aldol/dehydration, and SmI ₂ -mediated 4- exo -trig reductive cross-coupling. This meticulously designed synthetic strategy establishes a general solution to a problem previously deemed intractable by biomimetic approaches.
SN - 2041-1723
ER -